Executive Summary

The medical technology (medtech) industry is entering a period of accelerated change, driven by five structural forces: China's expanding volume-based procurement (VBP), the continued shift of procedures to outpatient and ambulatory surgical centers (ASCs), global supply chain instability, the clinical and market impact of GLP-1 receptor agonists, and the rise of platform-based competition enabled by robotics, imaging, navigation, and digital workflow software. For medtech companies, these trends are not isolated; they are converging to redefine how value is created, how products are priced and reimbursed, and how competitive advantage is sustained. This article analyzes each trend, its commercial impact, and the strategic implications for global healthcare markets.

Introduction

For decades, medtech success was built on incremental product innovation, clinician relationships, and procedure volume growth in hospital settings. The operating environment for 2026 suggests a different reality. Pricing pressure is intensifying across major markets, care delivery is moving to lower-cost settings, supply chains are being restructured, and new therapeutic paradigms are altering procedure demand. At the same time, enabling technologies are shifting the basis of competition from standalone devices to integrated platforms. The medtech companies that thrive will be those that adapt their strategies to these structural shifts and treat them as opportunities for transformation rather than threats to legacy models.

Business Context

The global medtech market is worth hundreds of billions of dollars, with growth historically supported by aging populations, rising chronic disease burdens, and technological innovation. However, the 2020s have brought a more complex environment. Price transparency, value-based reimbursement, and procurement reforms are constraining revenue growth. Geopolitical tensions and trade policies are forcing supply chain reconfiguration. And the entry of tech companies into healthcare is raising the bar for digital integration. Against this backdrop, the five trends identified by Clarivate's Medtech Trends to Watch 2026 provide a framework for understanding where the industry is headed.

Main Analysis

1. Mainland China's VBP Expansion Is Redefining Global Market Economics

Mainland China's volume-based procurement program, originally designed to expand patient access and lower device costs, has evolved into a powerful market-structuring mechanism. The latest round introduces more sophisticated anchor-price logic, deeper price compression, and allocation systems that favor domestic manufacturers. For multinational companies, VBP is no longer a localized policy issue; it sets expectations for price, volume, and competitive positioning that reverberate across global portfolios. As VBP expands into new product categories, companies must decide which markets to defend, how to price for access, and how to structure manufacturing to maintain margins. The program also accelerates domestic innovation, as Chinese competitors gain scale in high-volume segments and move up the value chain.

2. Outpatient and ASC Settings Are Becoming Central to Procedure Strategy

The migration of procedures from hospitals to outpatient settings is accelerating. In the United States, the Centers for Medicare & Medicaid Services (CMS) 2026 Hospital Outpatient Prospective Payment System (OPPS) and Ambulatory Surgical Center (ASC) Payment System Final Rule expands the ASC Covered Procedure List and phases out the inpatient-only list. This opens the door for higher-acuity procedures, such as cardiac ablation, to move into ASCs when clinically appropriate. For medtech companies, this shift has profound implications. Commercial models must adapt to different customer segments—ASCs are more price-sensitive and require simplified products, streamlined training, and tangible economic value propositions. Product design may need to evolve for smaller spaces and shorter procedure times. Companies that successfully address the ASC market can capture growth, while those tied to hospital-centric models risk losing share.

3. Global Trade and Supply Chain Pressures Are Reshaping Manufacturing Strategy

Tariff exposure, geopolitical tensions, and fluctuating material costs are challenging long-standing assumptions about where and how medical devices are produced. Companies are diversifying sourcing, re-evaluating manufacturing footprints, and pursuing multi-region strategies to build resilience. Larger manufacturers are using scale, integration, and technology investment to buffer against global volatility, which could consolidate market power. The strategic importance of supply chain is rising: cost structures, supplier concentration, and manufacturing geography are becoming sources of competitive advantage or disadvantage. Medtech leaders must embed supply chain risk into M&A decisions, product portfolio planning, and capital expenditure priorities.

4. GLP-1 Therapies Are Shifting Patient Behavior and Reshaping Care Pathways

The rapid adoption of glucagon-like peptide-1 (GLP-1) receptor agonists for weight management and metabolic disease is altering referral patterns and procedure demand. While bariatric surgery remains the most effective intervention for substantial weight loss, GLP-1 therapies are expanding the treatment population and changing the sequencing of care. Some bariatric procedures are experiencing volume pressure, while others are less affected. Downstream effects are emerging across adjacent device markets, including diabetes care, sleep apnea, and cardiovascular monitoring. Medtech companies must reassess their therapy area forecasts, identify which procedures are most exposed, and develop strategies that account for a new era of metabolic disease management. This trend also highlights the importance of cross-sector intelligence and adaptive portfolio management.

5. Enabling Technologies Are Driving the Shift Toward Platform-Based Competition

Robotics, imaging, navigation, and digital workflow software are no longer adjuncts to procedures; they are becoming the foundation of integrated ecosystems. Companies are investing heavily in platform architectures that anchor entire service lines, from pre-operative planning to surgical execution and post-operative care. These platforms generate data, deepen customer relationships, and create new value propositions. Emerging open-platform systems are increasing flexibility and intensifying competition. The strategic imperative is to move beyond single devices and build a technology stack that supports a broader clinical workflow. Success will depend on the ability to integrate hardware, software, and data analytics, and to manage partnerships across complementary technologies.

Commercial Impact

The trends described above have direct commercial implications. Pricing pressure compresses margins and forces portfolio rebalancing. Outpatient migration changes sales territories, service models, and value communication. Supply chain shifts alter cost structures and risk profiles. GLP-1 therapies disrupt procedure volumes and create new market dynamics. Platform competition changes what customers buy and how they perceive value. For investors, these trends affect revenue growth forecasts, profitability outlooks, and valuation multiples. For healthcare providers, they shape technology adoption decisions and capital investments. For patients, the combined effect is broader access to some treatments, potentially lower costs, and more integrated care pathways.

Strategic Insights

• Portfolio strategy: Companies must evaluate which product categories are exposed to VBP and adjust R&D investment toward higher-differentiation areas.
• Commercial model redesign: The shift to ASCs requires a new approach to sales, marketing, and customer support.
• Manufacturing resilience: A multi-region manufacturing footprint is becoming a strategic necessity, not a cost option.
• Cross-sector intelligence: The GLP-1 effect demands active monitoring of adjacent therapy areas and early scenario planning.
• Platform investment: Building or acquiring enabling technology capabilities is essential to remain competitive across service lines.

Future Outlook

Over the next three to ten years, these trends will intensify. VBP will likely expand to more categories and could become a model for other large markets seeking price control. Outpatient and ASC care will continue to grow, driven by technological advances, reimbursement changes, and patient preference. Supply chain strategies will evolve toward regionalized “glocal” networks. GLP-1 therapies may reshape the entire metabolic disease ecosystem, potentially reducing the demand for certain interventional procedures. Platform competition will blur the boundaries between device manufacturers and health technology companies. The medtech companies that succeed will be those that embrace complexity, invest in intelligence, and foster a culture of continuous strategic transformation.

Conclusion

The medtech industry's 2026 landscape is defined by interlocking structural changes. The companies that navigate these shifts successfully will not be those that simply optimize current product portfolios, but those that rethink their business models from the ground up. By understanding the economic forces behind China's procurement reforms, the logistics of outpatient care, the vulnerability of global supply chains, the clinical influence of GLP-1s, and the power of digital platforms, medtech leaders can position their organizations for sustainable growth. The imperative is clear: adapt strategically, or risk being left behind in an increasingly competitive and consolidated global market.

Key Takeaways

• China's VBP is a global price anchor, requiring multinational medtech companies to develop market-specific strategies.
• Outpatient and ASC settings are becoming a source of growth; commercial models must be redesigned to serve these customers.
• Supply chain resilience is a competitive differentiator, prompting diversification and regionalized manufacturing.
• GLP-1 therapies are reshaping procedure demand, especially in metabolic and cardiovascular device markets.
• Platform-based ecosystems, integrating robotics, imaging, and digital workflows, are the new frontier of competition.
• Strategic decision-making must incorporate trade policy, reimbursement changes, and clinical innovation concurrently.

SEO Keywords

Medtech trends 2026, global healthcare markets, volume-based procurement, outpatient care, ambulatory surgical centers, medical device supply chain, GLP-1 therapies, platform competition, medtech industry strategy, healthcare technology.

Sources

• Clarivate. “Medtech Trends to Watch in 2026.” Link